PCM
RPTX

Pentwater Capital Management’s Repare Therapeutics RPTX Stock Holding History

Pentwater Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,500
Closed -$463K – 377
2020
Q4 		$463K Buy
13,500
+5,000
+59% +$149K 0.01% 198
2020
Q3 		$262K Sell
8,500
-5,000
-37% -$132K ﹤0.01% 208
2020
Q2 		$419K Buy
+13,500
New +$433K 0.01% 129

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Pentwater Capital Management's RPTX Position: Q1 2021 in Review

Pentwater Capital Management sold out of Repare Therapeutics (RPTX) in Q1 2021, closing a stake of 13,500 shares — an estimated $463K sold.

Pentwater Capital Management first reported a position in RPTX in Q2 2020 and held it in 3 quarters. The position peaked at $463K in Q4 2020. 65 funds tracked by Wall St. Rank hold RPTX as of Q1 2021.

  • Pentwater Capital Management reported no remaining Repare Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 13,500 Repare Therapeutics shares in Q1 2021, an estimated $463K.
  • Pentwater Capital Management first reported a position in Repare Therapeutics in Q2 2020 and held it in 3 quarters.
  • Pentwater Capital Management's Repare Therapeutics position peaked at $463K in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2021.

Based on Pentwater Capital Management's 13F filing for Q1 2021, filed 17 May 2021.